Canada - English - Health Canada

takeda canada inc - antihemophilic factor (recombinant), pegylated - kit - 500unit - antihemophilic factor (recombinant), pegylated 500unit - hemostatics

Canada - English - Health Canada

takeda canada inc - antihemophilic factor (recombinant), pegylated - kit - 750unit - antihemophilic factor (recombinant), pegylated 750unit - hemostatics

Canada - English - Health Canada

takeda canada inc - antihemophilic factor (recombinant), pegylated - kit - 750unit - antihemophilic factor (recombinant), pegylated 750unit - hemostatics

Canada - English - Health Canada

takeda canada inc - antihemophilic factor (recombinant), pegylated - kit - 1000unit - antihemophilic factor (recombinant), pegylated 1000unit - hemostatics

Canada - English - Health Canada

takeda canada inc - antihemophilic factor (recombinant), pegylated - kit - 1500unit - antihemophilic factor (recombinant), pegylated 1500unit - hemostatics

Canada - English - Health Canada

takeda canada inc - antihemophilic factor (recombinant), pegylated - kit - 1500unit - antihemophilic factor (recombinant), pegylated 1500unit - hemostatics

Canada - English - Health Canada

takeda canada inc - antihemophilic factor (recombinant), pegylated - kit - 3000unit - antihemophilic factor (recombinant), pegylated 3000unit - hemostatics

United States - English - NLM (National Library of Medicine)

oncopeptides, ab - melphalan flufenamide hydrochloride (unii: 3412470a0v) (melphalan flufenamide - unii:f70c5k4786) - pepaxto is indicated in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one cd38-directed monoclonal antibody. this indication is approved under accelerated approval based on response rate. continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s) [see clinical studies (14)] . limitations of use pepaxto is not indicated and is not recommended for use as a conditioning regimen for transplant outside of controlled clinical trials [see warnings and precautions (5.5)]. pepaxto is contraindicated in patients with a history of serious hypersensitivity reaction to melphalan flufenamide or melphalan [see adverse reactions (6.1)] . risk summary based on its mechanism of action [see clinical pharmacology (12.1)] , pepaxto ca